Avalo Therapeutics (AVTX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$13.65
+1.6% on the day
-8.8% over 12 months
52-week range $12.74 – $22.87
Share price and insider trades
AVTX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$8.5M
Insiders buying0
Insiders selling6
Avalo Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $8.5M of AVTX stock on the open market.
Get emailed when insiders cluster-buy stocks like AVTX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AVTX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $2.0M | 10 |
| Q2 2026 | — | 0 | $6.0M | 30 |
| Q1 2026 | — | 0 | $412K | 1 |
| Q4 2025 | — | 0 | $163K | 2 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Avalo Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $8.5M. 40 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 18SEC | Christopher Ryan SullivanCFO | Sell Plan | 12,39439,900 held (−24%) | $16.33 | $202K | -16.4% | — |
| Sep 11SEC | Christopher Ryan SullivanCFO | Sell Plan | 10,18539,900 held (−20%) | $17.62 | $179K | -22.5% | — |
| Sep 1SEC | Mittie DoyleChief Medical Officer | Sell Plan | 67951,776 held (−1%) | $20.00 | $14K | -31.8% | — |
| Aug 19SEC | Christopher Ryan SullivanCFO | Sell Plan | 37,94543,649 held (−47%) | $19.85 | $753K | -31.2% | — |
| Aug 19SEC | Christopher Ryan SullivanCFO | Sell Plan | 31,03139,900 held (−44%) | $20.05 | $622K | -31.9% | — |
| Aug 19SEC | Christopher Ryan SullivanCFO | Sell Plan | 3,74939,900 held (−9%) | $19.94 | $75K | -31.5% | — |
| Aug 19SEC | Mittie DoyleChief Medical Officer | Sell Plan | 1,00051,776 held (−2%) | $20.00 | $20K | -31.8% | — |
| Aug 12SEC | Jennifer RileyChief Strategy Officer | Sell | 2,65537,041 held (−7%) | $19.59 | $52K | -30.3% | — |
| Aug 12SEC | Mittie DoyleChief Medical Officer | Sell Plan | 67951,776 held (−1%) | $20.00 | $14K | -31.8% | — |
| Jul 29SEC | Mittie DoyleChief Medical Officer | Sell Plan | 1,00051,776 held (−2%) | $20.00 | $20K | -31.8% | — |
| Jul 2SEC | Mittie DoyleChief Medical Officer | Sell Plan | 4,65451,776 held (−8%) | $20.00 | $93K | -31.8% | — |
| Jun 25SEC | Mittie DoyleChief Medical Officer | Sell Plan | 1,45051,776 held (−3%) | $18.00 | $26K | -24.2% | — |
| Jun 1SEC | Mittie DoyleChief Medical Officer | Sell Plan | 67947,122 held (−1%) | $16.00 | $11K | -14.7% | — |
| May 19SEC | Mittie DoyleChief Medical Officer | Sell Plan | 3,0003,622 held (−45%) | $18.76 | $56K | -27.2% | — |
| May 11SEC | Christopher Ryan SullivanCFO | Sell Plan | 18,606423 held (−98%) | $24.12 | $449K | -43.4% | — |
| May 7SEC | Mittie DoyleChief Medical Officer | Sell Plan | 44,94432,695 held (−58%) | $21.20 | $953K | -35.6% | — |
| May 7SEC | Paul VarkiGeneral Counsel | Sell Plan | 37,37541,322 held (−47%) | $18.91 | $707K | -27.8% | — |
| May 7SEC | Mittie DoyleChief Medical Officer | Sell Plan | 27,53882,639 held (−25%) | $18.03 | $497K | -24.3% | — |
| May 7SEC | Paul VarkiGeneral Counsel | Sell Plan | 22,83913,287 held (−63%) | $21.22 | $485K | -35.7% | — |
| May 7SEC | Mittie DoyleChief Medical Officer | Sell Plan | 19,01513,680 held (−58%) | $22.41 | $426K | -39.1% | — |
| May 7SEC | Christopher Ryan SullivanCFO | Sell Plan | 13,83433,589 held (−29%) | $18.55 | $257K | -26.4% | — |
| May 7SEC | Christopher Ryan SullivanCFO | Sell Plan | 12,34721,242 held (−37%) | $19.28 | $238K | -29.2% | — |
| May 7SEC | Mittie DoyleChief Medical Officer | Sell Plan | 10,0583,622 held (−74%) | $22.88 | $230K | -40.3% | — |
| May 7SEC | Paul VarkiGeneral Counsel | Sell Plan | 9,2534,034 held (−70%) | $22.70 | $210K | -39.9% | — |
| May 7SEC | Christopher Ryan SullivanCFO | Sell Plan | 8,900423 held (−95%) | $22.57 | $201K | -39.5% | — |
| May 7SEC | Christopher Ryan SullivanCFO | Sell Plan | 9,2199,323 held (−50%) | $21.37 | $197K | -36.1% | — |
| May 7SEC | Paul VarkiGeneral Counsel | Sell Plan | 5,19636,126 held (−13%) | $19.78 | $103K | -31.0% | — |
| May 7SEC | Mittie DoyleChief Medical Officer | Sell Plan | 5,00077,639 held (−6%) | $19.65 | $98K | -30.5% | — |
| May 7SEC | Mitchell ChanDirector | Sell Plan | 3,1673,166 held (−50%) | $22.88 | $72K | -40.3% | — |
| May 7SEC | Christopher Ryan SullivanCFO | Sell Plan | 2,70018,542 held (−13%) | $20.76 | $56K | -34.2% | — |
| May 7SEC | Mittie DoyleChief Medical Officer | Sell Plan | 1,6793,622 held (−32%) | $16.00 | $27K | -14.7% | — |
| May 7SEC | Paul VarkiGeneral Counsel | Sell Plan | 4003,634 held (−10%) | $23.71 | $9K | -42.4% | — |
| May 1SEC | Christopher Ryan SullivanCFO | Sell Plan | 8,457423 held (−95%) | $13.23 | $112K | +3.2% | — |
| May 1SEC | Christopher Ryan SullivanCFO | Sell Plan | 8,4588,880 held (−49%) | $13.09 | $111K | +4.3% | — |
| Apr 8SEC | Mittie DoyleChief Medical Officer | Sell Plan | 3,9703,622 held (−52%) | $18.01 | $71K | -24.2% | — |
| Apr 3SEC | Christopher Ryan SullivanCFO | Sell Plan | 7,47925,318 held (−23%) | $16.83 | $126K | -18.9% | — |
| Apr 3SEC | Christopher Ryan SullivanCFO | Sell Plan | 6,20019,118 held (−24%) | $17.02 | $106K | -19.8% | — |
| Apr 3SEC | Christopher Ryan SullivanCFO | Sell Plan | 1,78017,338 held (−9%) | $17.57 | $31K | -22.3% | — |
| Apr 3SEC | Mittie DoyleChief Medical Officer | Sell Plan | 6793,622 held (−16%) | $16.00 | $11K | -14.7% | — |
| Apr 3SEC | Christopher Ryan SullivanCFO | Sell Plan | 50032,797 held (−2%) | $15.86 | $8K | -13.9% | — |
| Mar 18SEC | Mittie DoyleChief Medical Officer | Sell Plan | 25,4923,622 held (−88%) | $16.15 | $412K | -15.5% | — |
| Nov 17SEC | Jonathan GoldmanDirector | Sell | 8,200 | $14.35 | $118K | -4.9% | — |
| Nov 17SEC | Jonathan GoldmanDirector | Sell | 3,167 | $14.30 | $45K | -4.5% | — |
Insiders at Avalo Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Christopher Ryan SullivanCFO | — | $3.7M | Sep 18, 2026 | — |
| Mittie DoyleChief Medical Officer | — | $3.0M | Sep 1, 2026 | — |
| Paul VarkiGeneral Counsel | — | $1.5M | May 7, 2026 | — |
| Jonathan GoldmanDirector | — | $163K | Nov 17, 2025 | — |
| Mitchell ChanDirector | — | $72K | May 7, 2026 | — |
| Jennifer RileyChief Strategy Officer | — | $52K | Aug 12, 2026 | — |
AVTX stock: common questions
Are Avalo Therapeutics, Inc. insiders buying AVTX stock?
In the past 12 months, 0 insiders reported open-market purchases of AVTX worth $0.
Are Avalo Therapeutics, Inc. insiders selling AVTX stock?
6 insiders reported sales worth $8.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AVTX's 52-week range?
Over the past year AVTX has traded between $12.74 and $22.87. It last closed at $13.65 on Oct 9, 2026.